Allergy Therapeutics Plc (AGY) Ord GBP0.01
Share news, reports & tips
13 January 2021 09:21
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics said on Wednesday that it was trading in line with expectations, with revenues growing in the first half of the trading year despite...
5 January 2021 16:44
(Sharecast News) - Speciality allergy-focussed pharmaceutical company Allergy Therapeutics announced on Tuesday that an ex-vivo biomarker study of blood samples from peanut allergy patients had started at...
26 October 2020 13:37
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the screening of the first patient in its exploratory field study 'G309', to evaluate the efficacy and safety of...
3 September 2020 15:31
(Sharecast News) - Biotechnology company Allergy Therapeutics announced further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field on Thursday.
15 July 2020 09:03
(Sharecast News) - Biotechnology company Allergy Therapeutics reported a "strong" full-year performance on Wednesday despite challenges stemming from the Covid-19 pandemic.
9 July 2020 16:26
(Sharecast News) - Biotechnology company Allergy Therapeutics announced the outcome of scientific advice from the German Regulatory Authority, the Paul Ehrlich Institute (PEI), over invalidation of the...
24 June 2020 10:12
(Sharecast News) - Biotechnology company Allergy Therapeutics said on Wednesday that its 2020 trading performance was on track to exceed market expectations.
26 November 2019 14:15
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market on its grass MATA MPL phase 3 study, due to start in autumn 2020, on Tuesday, reporting that following further...
27 June 2019 10:07
(Sharecast News) - Biotechnology group Allergy Therapeutics told investors on Thursday that 2019 full-year earnings looked set to come in ahead of market expectations.
20 May 2019 11:00
(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive Phase 1 safety and tolerability results of subcutaneous \'Acarovac MPL\' (monophosphoryl lipid A) in patients with...
25 April 2019 10:01
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics will kick off phase III trials of its short-course inoculation for grass pollen-induced hay fever in the second half of 2020 following...
18 March 2019 08:51
(Sharecast News) - Shares in biotechnology company Allergy Therapeutics were plunging on Monday morning, after it announced disappointing top-line results from the phase 3 clinical trial 'B301' of...
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2021. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.